IGC Pharma Inc (IGC)

NYSEAMERICAN: IGC · IEX Real-Time Price · USD
0.350
+0.005 (1.57%)
Mar 1, 2024, 4:00 PM EST - Market closed
1.57%
Market Cap 22.31M
Revenue (ttm) 1.22M
Net Income (ttm) -14.15M
Shares Out 63.73M
EPS (ttm) -0.26
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 316,852
Open 0.368
Previous Close 0.345
Day's Range 0.333 - 0.368
52-Week Range 0.250 - 0.500
Beta 2.29
Analysts n/a
Price Target n/a
Earnings Date Feb 14, 2024

About IGC

IGC Pharma, Inc., a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer's disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease comprising IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63 that is in pre-clinical development. It also markets Holief, a wellness brand that targets women experienci... [Read more]

Industry Conglomerates
Sector Industrials
Founded 2005
Employees 61
Stock Exchange NYSEAMERICAN
Ticker Symbol IGC
Full Company Profile

Financial Performance

In 2022, IGC Pharma's revenue was $911,000, an increase of 129.47% compared to the previous year's $397,000. Losses were -$11.51 million, -23.38% less than in 2021.

Financial Statements

News

IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price Target

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Ascendiant Coverage.

9 days ago - Business Wire

IGC Pharma Reports Third Quarter Fiscal 2024 Results

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Reports Third Quarter Fiscal 2024 Results.

16 days ago - Business Wire

IGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's Mouse Model

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--TGR-63 Reduces Agitation in Alzheimer's Mouse Model.

4 weeks ago - Business Wire

IGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer's

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Breakthrough - Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer's.

5 weeks ago - Business Wire

IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer's Trial

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer's Trial.

6 weeks ago - Business Wire

Patent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer's

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--Patent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer's.

2 months ago - Business Wire

IGC Pharma Announces Participation in Biotech Showcase and BioPartnering @ JPM Alongside the J.P. Morgan 41st Annual Healthcare Conference 2024

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Announces Participation in Biotech Showcase and BioPartnering @ JPM Alongside the J.P. Morgan 41st Annual Healthcare Conference 2024.

2 months ago - Business Wire

IGC Pharma Announces Collaboration to Integrate AI into Clinical Trials

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American: IGC) today announced an Artificial Intelligence (AI) collaboration with Los Andes University's Center for...

3 months ago - Business Wire

IGC Pharma Announces Master Agreement with Leading South American University to Advance AI Initiatives

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Announces Master Agreement with Leading South American University to Advance AI Initiatives.

3 months ago - Business Wire

IGC Pharma Reports Second Quarter Fiscal 2024 Results

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Reports Second Quarter Fiscal 2024 Results.

3 months ago - Business Wire

IGC Pharma Granted European Patent for Groundbreaking Cannabinoid-Based Pain Topical Relief Therapy

POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC Pharma Granted European Patent for Groundbreaking Cannabinoid-Based Pain Topical Relief Therapy.

4 months ago - Business Wire

IGC Pharma Reports First Quarter Results; Company Continues to Make Significant Progress Advancing Its Lead Alzheimer's Candidate Through Phase 2 Clinical Trials

POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC Pharma Reports First Quarter Results; Company Continues to Make Significant Progress Advancing Its Lead Alzheimer's Candidate.

7 months ago - Business Wire

IGC Pharma Expands Phase 2 Trial of IGC-AD1 to Include the University of Puerto Rico

POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC Pharma Expands Phase 2 Trial of IGC-AD1 to Include the University of Puerto Rico.

7 months ago - Business Wire

IGC Pharma, Inc. Presenting 6 Posters on the Positive Impact of IGC-AD1 on Neuropsychiatric Symptoms in Dementia at the 2023 Alzheimer's Association International Conference

POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC 's 6 Posters on Positive Impact of IGC-AD1 on Neuropsychiatric Symptoms of Dementia at 2023 Alzheimer's Association International Conference.

8 months ago - Business Wire

IGC Pharma Secures $12 Million Line of Credit from O-Bank Strengthening Efforts in Alzheimer's Research

POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC Pharma Secures $12 Million Line of Credit from O-Bank Strengthening Efforts in Alzheimer's Research.

8 months ago - Business Wire

IGC Pharma Announces a $3 Million Private Placement of its Common Stock

POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC Pharma Announces a $3 Million investment: strengthen IGC's working capital & support the advancement of our IGC-AD1 Phase-2 clinical trial.

8 months ago - Business Wire

IGC Pharma Receives Notice of Allowance for Patent on Seizures

POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC received Notice of Allowance from Commissioner of Patents, Canada, for its patent filing on the use of cannabinoids in the treatment of seizures.

9 months ago - Business Wire

IGC Pharma's Advisor and Inventor of Drug Candidate TGR-63 Receives Award

POTOMAC, Maryland--(BUSINESS WIRE)-- #IGC--Professor T. Govindaraju, IGC Pharma's Advisor and Inventor of Drug Candidate TGR-63 Receives Award .

9 months ago - Business Wire

IGC Pharma to Present at LD Micro Invitational XIII

Presentation on Tuesday, June 6 at 3:00 PM PT Los Angeles, California--(Newsfile Corp. - May 18, 2023) - IGC Pharma, Inc. (NYSE American: IGC) announced today that it will be presenting at the 13th An...

10 months ago - Newsfile Corp

IGC Pharma, Inc. to Present at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023 & Hold 1x1 Meetings on Thursday, April 27, 2023

POTOMAC, MD / ACCESSWIRE / April 18, 2023 / IGC Pharma, Inc. (NYSE American:IGC) today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023, at...

11 months ago - Accesswire

IGC Announces Rebranding, Changes Name to IGC Pharma, Inc.

POTOMAC, Md., March 20, 2023 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announces it will begin operating under the new name IGC Pharma, ...

1 year ago - GlobeNewsWire

IGC Reports Financial Results for Third Fiscal Quarter Ended Dec. 31, 2022

POTOMAC, Md., Feb. 14, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- India Globalization Capital, Inc. (dba IGC, Inc.) (NYSE American: IGC) (“IGC” or the “Company”) today reported its third fiscal quar...

1 year ago - GlobeNewsWire

IGC to be Featured in Feb. 10 Radius Research Investor Webinar

POTOMAC, Md., Feb. 08, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announces that Ram Mukunda, CEO, and Claudia G...

1 year ago - GlobeNewsWire

LTK Releases 2023 State of Creator Guided Shopping Trends Report

DALLAS--(BUSINESS WIRE)--Over the past year the influencer marketing industry remained resilient and continued to grow in its role and impact for marketers, reaching an estimated value of $16.4 bill...

1 year ago - Business Wire

IGC Receives No Objection Letter from Health Canada

POTOMAC, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announces it has received a no objection lette...

1 year ago - GlobeNewsWire